Notable Labs

Notable Labs CapEx/D&A

The CapEx to Depreciation Ratio of Notable Labs (NTBLQ) as of Nov 17, 2026 is 40.50. In the previous year, CapEx to Depreciation Ratio was 3.77 — a change of 974.49% (higher).

CapEx/D&A

40.50

YoY

974.49%

Last updated:

CapEx to Depreciation Ratio of Notable Labs is 2017 40.50 . CapEx to Depreciation Ratio of Notable Labs was 2016 3.77 . It decreases by 974.49% higher compared to the previous year.

The Notable Labs CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2014
0.43 USD
Jan 1, 2015
0.75 USD
Jan 1, 2016
3.77 USD
Jan 1, 2017
40.50 USD
The Notable Labs CapEx/D&A history
YEARCapEx/D&AYoY
40.50+974.49%
3.77+402.56%
0.75+75.00%
0.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

CapEx to Depreciation Ratio of Notable Labs is 40.50 in 2017.

CapEx to Depreciation Ratio of Notable Labs changed from 3.77 to 40.50, representing a 974.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Notable Labs since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Notable Labs

All Key Metrics — Notable Labs